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Previews
reactivity for MHC across species is termed xenoreac-Glimpses at TCR Trans-Species
tivity. For instance, in mice devoid of H-2 class Ia mol-Crossreactivity ecules, the mouse TCR repertoire is capable of
recognizing transgenic human HLA molecules, although
with a greatly reduced efficiency (Firat et al., 2002). Im-
portantly, the recognition of human MHCI molecules by
Binding degeneracy (or crossreactivity) constitutes an mouse TCRs needs to occur in a coreceptor-indepen-
important attribute of TCR recognition, and crossrec- dent manner since mouse CD8 molecules do not de-
ognized ligands consist not only of distinct peptides tectably bind to human MHCI molecules. By elucidating
presented by self-MHC molecules but can also involve the structure of a mouse TCR bound to a human MHC
MHC molecules belonging to other species. In this molecule, Buslepp et al. (2003) provide the first hints on
issue, Buslepp et al. provide a basis for this trans- the structural basis of xenoreactivity. The mouse CD8
species crossreactivity, elucidated by the crystal CTL clone they used to prepare soluble TCRs is denoted
structure of a complex involving a mouse TCR and a AHIII 1.22 and recognizes the human HLA-A2 molecule
human MHC molecule. complexed with a peptide designated p1049 in a CD8-
independent manner. AHIII 1.22 also recognizes the
mouse class I molecule H-2Db complexed with a distinctBecause the diversity of peptide-MHC (pMHC) ligands
peptide, but in a CD8-dependent manner.that can be encountered greatly exceeds the number
Important conclusions can be deduced from the AHIIIof T cell clones present in an individual at any one time,
1.22-p1049-HLA-A2 crystal structure. First, xenoreac-the ability to recognize almost any pMHC with a limited
tive recognition is structurally equivalent to self-pMHCnumber of T cells and within a time frame compatible
and allo-pMHC recognition in that it follows the samewith the speed at which infectious agents spread, may
conserved docking orientation. Second, the p1049 pep-only be achieved via crossreactivity at the level of TCR-
tide constitutes an integral component of the epitopepMHC recognition (Mason, 1998). Conformational flexi-
recognized by the AHIII 1.22 TCR on the xenogeneicbility of complementarity-determining region 3 facili-
pMHC ligand. Third, together with a recent TCR-pMHCtates the adaptation of a given TCR to distinct pMHC
structure (Stewart-Jones et al., 2003), the data of Bus-surfaces, and likely accounts for TCR binding degener-
lepp et al. invalidate earlier views suggesting thatacy (Reiser et al., 2003).
MHCI-specific TCRs conformed to a “diagonal” dockingUnder physiological situations, TCR crossreactivity is
orientation, while MHCII-specific TCRs bound in a moreapparent during intrathymic T cell positive selection,
“orthogonal” manner. Relative to an axis defined by theand homeostatic survival in the periphery. The crossrec-
peptide main chain, the orientation angle for AHIII 1.22-ognized ligands consist of distinct peptides presented
p1049-HLA-A2 falls within the range seen for MHCII-
by the same self-MHC molecule. However, under experi-
specific TCRs.
mental or clinical conditions, TCRs can even react
It has been argued that the conserved orientation of
against MHC molecules not seen during thymic selec- the TCR over the pMHC corresponds to the fact that
tion. For instance, many TCRs selected to respond to the shape of the TCR and of the pMHC binding surfaces
foreign peptides bound to a self-MHC molecule express limits the number of docking orientations. However,
a concomitant crossreactivity for intraspecies allelic these considerations on complementary shapes would
variants of self-MHC molecules. This property, termed also be compatible with TCR engaging the pMHC with
alloreactivity, causes graft rejection and graft-versus- a 180 rotation relative to the observed orientation. A
host disease. Based on crystal structures of TCR-pMHC further raison d’eˆtre for the unique docking orientation
allocomplexes, it appears that during allorecognition, may be sought in the action of the CD4 and CD8 core-
TCRs neither avoid contacting the bound peptide nor ceptors. Provided that the MHCI molecule recruits CD8
focus on the polymorphic amino acids that are exposed to the  chain side of the TCR, and thereby permits
on the top of the allo-MHC  helices (Housset and Malis- the appropriate positioning of the CD8-associated Lck
sen, 2003). Although structures corresponding to the kinase in the vicinity of pMHC-occupied TCRs, it is plau-
same TCR in complex with a self- and an allo-MHC are sible that in the case of a TCR-pMHC docking geometry
not available yet, a parsimonious interpretation of the rotated by 180, the Lck kinase associated with the CD8
available data suggests that during allorecognition, coreceptor will be prevented from reaching its sub-
TCRs exploit the similarities rather than the differences strates. The data of Buslepp et al. (2003) further suggest
between the top of the  helices of self- and allo-MHC that even within the frame of the conserved TCR-pMHC
molecules, and that the high precursor frequency of orientation, some subtle docking variations that may
alloreactive T cells is accounted for by the fact that allo- directly influence the degree of CD8 dependence exist.
MHC molecules display a totally new constellation of Comparison of eight TCR-pMHCI and two TCR-pMHCII
endogenous peptides against which the repertoire of complexes shows that some wobble exists in the spe-
mature T cells has not been negatively selected in the cific position adopted by the variable (V) domains on
thymus (Housset and Malissen, 2003). the MHC surface. For instance, the projection on the
Some TCRs can even find compatible landmarks on MHC 2 helix surface of the center of mass of the V
domain of the eight MHCI-restricted TCRs defines twoMHC molecules belonging to other species. Such cross-
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distinct clusters. Four V domains cluster together data obtained in the BM3.3 system go against the model
proposed by Buslepp et al. (2003) and suggest that CD8within a patch closer to the amino terminus of the pep-
tide (patch N), and four V domains cluster within a dependence correlates with the relative affinities of the
BM3.3 TCR for the two pMHC ligands (using surfacepatch closer to the carboxy terminus of the peptide
(patch C). TCRs using patch N turned out to be CD8 plasmon resonance, BM3.3 TCR was found to bind
VSV8-H-2Kb with a KD of 114 M and pBM1-H-2Kb withdependent, whereas those using patch C were CD8 in-
dependent. According to Buslepp et al. (2003), docking a KD of 2.6M), rather than with the adoption of a permis-
sive TCR docking topology.on patch N permits proper positioning of the CD8-bound
Lck relative to its substrate, whereas docking on patch Although the data of Buslepp et al. (2003) complete
our structural views on the whole spectrum of TCRC hinders optimal positioning of CD8-bound Lck. As a
consequence, only high-affinity TCRs capable of func- crossreactivities, it should be emphasized that there
exists no absolute definition of TCR crossreactivity. Thistioning in a CD8-independent mode have the potential
to use patch C. attribute constitutes an empirical and assay-dependent
property, and accordingly the sensitivity of some in vitroConsidering that positive selection of most MHCI-
restricted TCRs depends on CD8, Buslepp et al. (2003) assays is sometimes much too high and reveals crossre-
activities that are not biologically relevant. Moreover,further posit that TCRs are selected in the thymus with
a docking geometry involving patch N. However, once the range of crossreactivity exhibited by a given TCR is
not a property intrinsic to the TCR but also depends onin the periphery and provided it results in high-affinity
CD8-independent interaction, some of them, exempli- the developmental stage and/or activation status of the
T cell clone that expresses it, and on the structure offied by AHIII 1.22, can adopt a novel docking geometry
involving repositioning of their V domain on patch C. the signaling cassette that acts downstream of it. For
instance, it has been shown that the protein tyrosineAlthough the possibility for a given V domain to adopt
alternative docking registers when binding to the same phosphatase SHP-1 increases the specificity of TCR
signaling by inhibiting signals corresponding to TCR-MHC 2 helix remains to be documented, some support
for the above views can be found in the fact that there pMHC interactions with short half-lives. Conversely, a
state of TCR-signaling hypersensitivity, resulting inclearly exist more than one docking solution between a
given V domain and a given MHC 1 helix (Housset markedly broadened ligand crossreactivity, can be in-
duced during lymphopenia, following adhesion-inducedand Malissen, 2003). In contrast to the views of Buslepp
et al. (2003), we (Reiser et al., 2000) and others (Hen- T cell priming, or in the presence of CD8. Therefore,
predicting ab initio TCR (or more appropriately T cell)necke and Wiley, 2002; Speir et al., 1998) have argued
that for a given TCR there will be no global repositioning crossreactivity with the aim of optimizing peptide vac-
cines or of preventing autoimmunity remains a daunt-of the V domains on the MHC surface when docking
on intrathymic selecting self-pMHC ligand, on foreign ing challenge.
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